SAR444881 + pembrolizumab + carboplatin + pemetrexed

SAR444881 + pembrolizumab + carboplatin + pemetrexed is an investigational combination therapy for advanced or metastatic solid tumors, with ongoing clinical studies in non-squamous non-small cell lung cancer (NSCLC), among other cancer indications[1][9]. - **SAR444881** is an anti-TIGIT monoclonal antibody developed for cancer immunotherapy, aiming to enhance antitumor immune responses through inhibition of the TIGIT checkpoint pathway. - **Pembrolizumab** (Keytruda) is an anti–PD-1 monoclonal antibody that blocks interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T cell–mediated immune response against tumor cells. - **Carboplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks, inhibiting DNA synthesis and function, leading to apoptosis in rapidly dividing tumor cells. - **Pemetrexed** is an antifolate chemotherapy agent that disrupts folate-dependent metabolic processes essential for cell replication. The combination is being evaluated for improved efficacy compared to standard chemotherapy and immunotherapy regimens in advanced/metastatic NSCLC and other tumor types[1][9].

Other names

pembrolizumabcarboplatinpemetrexed